Hormone replacement therapy after breast cancer

被引：0

作者：

Ortmann, O. ^{[1
]}

机构：

[1] Lehrstuhl Univ Regensburg, Caritas Krankenhaus St Josef, Klin Frauenheilkunde & Geburtshilfe, Landshuter Str 65, D-93053 Regensburg, Germany

来源：

GYNAKOLOGISCHE ENDOKRINOLOGIE | 2019年 / 17卷 / 03期

关键词：

Estrogens; Quality of life; Hot flashes; Risk for breast cancer; Progestins; SYMPTOMS; EFFICACY; SAFETY; RISK;

D O I：

10.1007/s10304-019-0256-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

During and after treatment of the disease, female patients with breast cancer often suffer from symptoms that are due to low estrogen levels. These can lead to a relevant impairment of the quality of life. Estrogens can relieve the symptoms; however, in this situation they are fundamentally contraindicated. Most therapeutic alternatives are, however, often insufficient for symptom control. In exceptional cases treatment with estrogens can be considered in patients with particularly severe impairments of the quality of life. This review article describes the possible risks and treatment strategies.

引用

页码：172 / 174

页数：3

共 12 条

[1]

[Anonymous], 2018, PER POSTM DIAGN INT

[2] Treatment of climacteric symptoms in breast cancer patients: A retrospective study from a medication databank [J].

Antoine, Caroline ;

Ameye, Lieveke ;

Paesmans, Marianne ;

Rozenberg, Serge .

MATURITAS, 2014, 78 (03) :228-232

[3] Breast cancer risk with postmenopausal hormonal treatment [J].

Collins, JA ;

Blake, JM ;

Crosignani, PG .

HUMAN REPRODUCTION UPDATE, 2005, 11 (06) :545-560

[4]

Davis SR, 2014, MENOPAUSE, V21, P1075, DOI [10.1097/GME.0000000000000219, 10.1097/gme.0000000000000219]

[5] Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (GynoflorA®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study [J].

Donders, Gilbert ;

Neven, Patrick ;

Moegele, Maximilian ;

Lintermans, Anneleen ;

Bellen, Gert ;

Prasauskas, Valdas ;

Grob, Philipp ;

Ortmann, Olaf ;

Buchholz, Stefan .

BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (02) :371-379

[6] Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial [J].

Fahlen, Mia ;

Fornander, Tommy ;

Johansson, Hemming ;

Johansson, Ulla ;

Rutqvist, Lars-Erik ;

Wilking, Nils ;

von Schoultz, Eva .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (01) :52-59

[7]

Farquhar C, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003139.pub2, 10.1002/14651858.CD001122.pub2, 10.1002/14651858.CD004143.pub2]

[8] HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped [J].

Holmberg, L ;

Anderson, H .

LANCET, 2004, 363 (9407) :453-455

[9] Increased risk of recurrence after hormone replacement therapy in breast cancer survivors [J].

Holmberg, Lars ;

Iversen, Ole-Erik ;

Rudenstam, Carl Magnus ;

Hammar, Mats ;

Kumpulainen, Eero ;

Jaskiewicz, Janusz ;

Jassem, Jacek ;

Dobaczewska, Daria ;

Fjosne, Hans E. ;

Peralta, Octavio ;

Arriagada, Rodrigo ;

Holmqvist, Marit ;

Maenpa, Johanna .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (07) :475-482

[10] Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial [J].

Kenemans, Peter ;

Bundred, Nigel J. ;

Foidart, Jean-Michel ;

Kubista, Ernst ;

von Schoultz, Bo ;

Sismondi, Piero ;

Vassilopoulou-Sellin, Rena ;

Yip, Cheng Har ;

Egberts, Jon ;

Mol-Arts, Mirjam ;

Mulder, Roel ;

van Os, Steve ;

Beckmann, Matthias W. .

LANCET ONCOLOGY, 2009, 10 (02) :135-146

← 1 2 →